LNTH vs. TEVA, BGNE, GMAB, VTRS, ITCI, SMMT, MRNA, RDY, CTLT, and SRPT
Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry.
Lantheus vs.
Teva Pharmaceutical Industries (NYSE:TEVA) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.
54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 1.5% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Teva Pharmaceutical Industries received 988 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 67.82% of users gave Teva Pharmaceutical Industries an outperform vote while only 65.89% of users gave Lantheus an outperform vote.
Lantheus has a net margin of 28.57% compared to Teva Pharmaceutical Industries' net margin of -5.73%. Lantheus' return on equity of 44.29% beat Teva Pharmaceutical Industries' return on equity.
Teva Pharmaceutical Industries has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.
In the previous week, Lantheus had 4 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 18 mentions for Lantheus and 14 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.77 beat Lantheus' score of 0.54 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.
Teva Pharmaceutical Industries presently has a consensus price target of $22.13, indicating a potential upside of 0.72%. Lantheus has a consensus price target of $131.86, indicating a potential upside of 44.15%. Given Lantheus' stronger consensus rating and higher possible upside, analysts plainly believe Lantheus is more favorable than Teva Pharmaceutical Industries.
Lantheus has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Summary
Lantheus beats Teva Pharmaceutical Industries on 13 of the 18 factors compared between the two stocks.
Get Lantheus News Delivered to You Automatically
Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantheus Competitors List
Related Companies and Tools
This page (NASDAQ:LNTH) was last updated on 1/20/2025 by MarketBeat.com Staff
Free LNTH Stock Alerts